Koninklijke Philips (NYSE:PHG – Get Free Report) is scheduled to announce its earnings results before the market opens on Monday, October 28th. Investors interested in participating in the company’s conference call can do so using this link.
Koninklijke Philips (NYSE:PHG – Get Free Report) last announced its quarterly earnings results on Monday, July 29th. The technology company reported $0.32 earnings per share for the quarter. Koninklijke Philips had a positive return on equity of 10.15% and a negative net margin of 2.35%. The firm had revenue of $4.80 billion during the quarter. On average, analysts expect Koninklijke Philips to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.
Koninklijke Philips Price Performance
Shares of Koninklijke Philips stock opened at $31.67 on Friday. The company has a quick ratio of 0.74, a current ratio of 1.16 and a debt-to-equity ratio of 0.60. Koninklijke Philips has a twelve month low of $18.06 and a twelve month high of $32.91. The business has a 50-day moving average price of $31.05 and a 200 day moving average price of $27.61. The firm has a market cap of $29.77 billion, a PE ratio of -59.75, a P/E/G ratio of 1.05 and a beta of 0.74.
Analysts Set New Price Targets
View Our Latest Analysis on Koninklijke Philips
Koninklijke Philips Company Profile
Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.
See Also
- Five stocks we like better than Koninklijke Philips
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Texas Roadhouse Stock Steering for New Highs This Year
- The How And Why of Investing in Oil Stocks
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Koninklijke Philips Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Koninklijke Philips and related companies with MarketBeat.com's FREE daily email newsletter.